Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment

Kevin Robertson, Alan Landay, Sachiko Miyahara, Alyssa Vecchio, Mary Clare Masters, Todd T. Brown, Babafemi O. Taiwo

Research output: Contribution to journalArticlepeer-review

Abstract

The AIDS Clinical Trials Group (ACTG) study A5303 investigated the associations between neuropsychological performance (NP) and inflammatory biomarkers in HIV-infected participants. Fifteen NP tests were administered at baseline and week 48 to 233 ART naïve participants randomized to maraviroc- or tenofovir-containing ART. Neurocognition correlated modestly with markers of lymphocyte activation and inflammation pre-ART (percent CD38+/HLA-DR+(CD4+) (r = − 0.22, p = 0.02) and percent CD38+/HLA-DR+(CD8+) (r = − 0.25, p = 0.02)), and with some monocyte subsets during ART (r = 0.25, p = 0.02). Higher interleukin-6 and percent CD38+/HLA-DR+(CD8+) were independently associated with worse severity of HIV-associated neurocognitive disorders (HAND) (p = 0.04 and 0.01, respectively). More studies to identify HAND biomarkers are needed.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalJournal of neurovirology
Volume26
Issue number1
DOIs
StatePublished - Feb 1 2020

Keywords

  • Antiretroviral therapy
  • Biomarker
  • Inflammation
  • Monocytes
  • Neurocognitive performance

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Virology

Fingerprint Dive into the research topics of 'Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment'. Together they form a unique fingerprint.

Cite this